MIR26B

Summary

MIR26B (microRNA 26b, HGNC:31612) is a microRNA gene on chromosome 2q35.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407017 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31612
Approved symbol	MIR26B
Name	microRNA 26b
Location	2q35
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-26b
Ensembl gene	ENSG00000199121
Ensembl biotype	miRNA
OMIM	612152
Entrez	407017
RNAcentral	URS000075C05A — miRNA, 77 nt, 24 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362251

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362251 — 1 exons

Exon	Start	End
ENSE00001437014	218402646	218402722

Expression profiles

Bgee: expression breadth broad, 72 present calls, max score 91.24.

Top tissues by expression

72 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	91.24	gold quality
blood	UBERON:0000178	79.49	gold quality
islet of Langerhans	UBERON:0000006	73.45	gold quality
monocyte	CL:0000576	73.30	gold quality
muscle layer of sigmoid colon	UBERON:0035805	72.39	gold quality
placenta	UBERON:0001987	72.26	gold quality
heart	UBERON:0000948	72.10	gold quality
heart left ventricle	UBERON:0002084	71.89	gold quality
body of pancreas	UBERON:0001150	70.89	gold quality
gastrocnemius	UBERON:0001388	70.88	gold quality
right atrium auricular region	UBERON:0006631	70.88	gold quality
tibial artery	UBERON:0007610	69.78	gold quality
stomach	UBERON:0000945	69.67	gold quality
prefrontal cortex	UBERON:0000451	69.43	gold quality
endometrium	UBERON:0001295	69.38	gold quality
urinary bladder	UBERON:0001255	69.23	gold quality
uterus	UBERON:0000995	68.46	gold quality
body of stomach	UBERON:0001161	68.22	gold quality
ascending aorta	UBERON:0001496	67.94	gold quality
ovary	UBERON:0000992	67.26	gold quality
left ovary	UBERON:0002119	67.26	gold quality
left adrenal gland cortex	UBERON:0035825	66.85	gold quality
granulocyte	CL:0000094	66.77	gold quality
left adrenal gland	UBERON:0001234	66.69	gold quality
transverse colon	UBERON:0001157	66.57	gold quality
putamen	UBERON:0001874	66.38	gold quality
esophagus mucosa	UBERON:0002469	66.18	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	66.14	gold quality
body of uterus	UBERON:0009853	66.07	gold quality
myometrium	UBERON:0001296	65.91	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.41

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• In patients with hepatocellular carcinoma, the expression of miR-26a and miR-26b in nontumor liver tissue was higher in women than in men. The miR-26 expression status of patients is associated with survival and response to therapy with interferon alfa. (PMID:19812400)
• The expression of miR-26b was significant decreased in HUES-17s and LoVo cells, compared with other three cell lines. (PMID:20831567)
• miR-26b may act as a tumor suppressor in glioma and it directly regulates EphA2 expression (PMID:21264258)
• Data show that SLC7A11 is the direct target of miR-26b and its expression is remarkably increased in both breast cancer cell lines and clinical samples. (PMID:21510944)
• Data concluded that IR-induced up-regulation of ATF2 was coordinately enhanced by suppression of miR-26b in lung cancer cells, which may enhance the effect of IR in the MAPK signaling pathway. (PMID:21901137)
• miR-15ab, miR-16, miR-26ab, miR-196ab and Let-7a as potential HMGA-targeting miRNAs. Interestingly, the targeting sites of these HMGA-targeting miRNAs on the 3’-UTR of HMGA1 and HMGA2 (PMID:22139073)
• miRNAs (miR-26a1/2 and miR-26b) downregulate BDNF expression and the presence of the variant alleles of two single nucleotide polymorphisms (rs11030100 and rs11030099) mapping in BDNF 3’UTR specifically abrogates miRNAs targeting. (PMID:22194877)
• Loss of miR-26b is associated with splenic marginal zone lymphoma in chronic hepatitis C virus infected patients. (PMID:22307176)
• miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. (PMID:22614013)
• miR-26a/b and miR-29b are upregulated during osteogenic differentiation of unrestricted somatic stem cells and share target genes inhibiting osteogenesis (PMID:23418963)
• Reversible downregulation of miR-26b strongly suggests the key role it plays in the pathogenesis of HCV-related lymphoproliferative disorders. (PMID:23650540)
• MiR-26b in breast carcinoma-associated fibroblasts is a potent regulator of cancer behaviour in oestrogen receptor-positive cancers. (PMID:23939832)
• This study showed that upregulation of miR-26b in neurons causes pleiotropic phenotypes that are also observed in AD. Elevated levels of miR-26b may thus contribute to the AD neuronal pathology. (PMID:24027266)
• miR-26b may be involved in adipogenesis and could be targeted for therapeutic intervention in obesity. (PMID:24140453)
• miR-26a and -26b were identified as key regulators of human white and brite adipocyte differentiation. (PMID:24375761)
• miR-26b suppresses NF-kappaB signaling and sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis by inhibiting the expression of TAK1 and TAB3. (PMID:24565101)
• Data indicate that chromodomain-helicase-DNA-binding protein CHD1, neoplasm protein GREB1 and karyopherin alpha 2 protein KPNA2 as critical mediators of miR-26a and miR-26b elicited cell growth. (PMID:24735615)
• Our analysis of clinical HCC samples verifies that miR-26b also targets USP9X expression to inhibit the EMT of hepatocytes (PMID:24890815)
• miR-26 family in cardiovascular disease plays a central role by controlling critical signaling pathways,such as BMP/ SMAD1 signaling,and targets relevant to endothelial cell growth,angiogenesis,and Left Ventricular function post-Myocardial Infarction. (PMID:25066487)
• The current study suggests that miR26a, miR26b, and CDC6 and factors regulating their expression represent potential cancer diagnostic and prognostic markers as well as anticancer targets. (PMID:25100863)
• This study demonstrated that MIR26b in patient with major depression disorder was up regulation in peripheral blood mononuclear cells. (PMID:25201637)
• suppression of miR-26b expression up-regulates its target gene CHORDC1, which increases HBV enhancer/promoter activities and promotes viral transcription, gene expression, and replication (PMID:25342750)
• miR-26b serves as a tumor suppressor by targeting COX-2 (PMID:25483152)
• This data suggests that ANXA1-regulated miR26b* and miR562 may play a role in wound healing and tumor-induced endothelial cell tube formation by targeting NF-kappaB expression and point towards a potential therapeutic target for breast cancer. (PMID:25536365)
• Data shows that miR-26a and miR-26b were significantly downregulated and their direct target, TMEM184B significantly up-regulated in oral squamous cell carcinoma cells. (PMID:25668004)
• A binding site for miR-26b was predicted in the 3’UTR of PFKFB3, suggesting a tumor suppressive role for miR-26b in metabolic alteration in osteosarcoma cells. miR-26b overexpression repressed PFKFB3 mRNA and protein levels. (PMID:25672572)
• Omega-3 polyunsaturated fatty acids upregulate the expression of 15-PGDH by inhibiting miR-26a and miR-26b. (PMID:25691459)
• Our data indicated that downregulation of miR-26b in osteosarcoma elevated the levels of CTGF and Smad1, facilitating osteosarcoma metastasis (PMID:25761878)
• miR-26b targeted CALM1 and affected the expression of CaM at the post-transcriptional level, which likely contributed to the progression of acute cerebral infarction brain injury. (PMID:26001204)
• Human preadipocytes overexpressing miR26b exhibited increased trigycerlide content in the adipocytes. (PMID:26016996)
• Data showed downregulation of miR-26a and miR-26b in prostate cancer and suggested them as tumor suppressors. They both targeted the 3’UTR of LARP1. (PMID:26063484)
• miR-26b was a negative regulator of Mcl-1 gene and sensitized TRAIL-inducing apoptosis in HCC cells, suggesting that the miR-26b-Mcl-1 pathway might be a novel target for the treatment of Hepatocellular Carcinoma . (PMID:26078955)
• miR-26b could serve as a biomarker for inflammation-associated processes in the gastrointestinal system and because its expression is downregulated in sporadic colon cancer, it could discriminate between UCC and the sporadic cancer type. (PMID:26083618)
• MiR-26b regulates beta-catenin levels by inhibiting GSK-3beta expression, which in-turn alters the Wnt/GSK-3beta/beta-catenin pathway to lower rheumatoid arthritis fibroblast-like synoviocyte proliferation and elevate cell apoptosis. (PMID:26088648)
• Overexpression of miR-26b dramatically inhibited the proliferation, invasion, and migration of hepatocellular carcinoma cells by targeting EphA2. (PMID:26191168)
• Reduced miR-26b was correlated with tumor development and poor prognosis in human cervical cancer. (PMID:26191262)
• Up-regulation of miR-26b occurs in respiratory syncytial virus infection following inhibition of TLR4 signaling. (PMID:26222045)
• MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression (PMID:26681033)
• miR-26b-3p played an important role in the regulation ofHuman umbilical cord-derived mesenchymal stem cells proliferation in vitro by targeting the ESR-CCND1 pathway. (PMID:26723394)
• miR-26b could suppress lung cancer cells proliferation, migration and invasion by directly negative regulation of COX-2. (PMID:26744864)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir26b	ENSMUSG00000065468
rattus_norvegicus	Mir26b	ENSRNOG00000035608

Paralogs (2): MIR26A1 (ENSG00000199075), MIR26A2 (ENSG00000207789)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.